Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1986-7-22
|
| pubmed:abstractText |
Between June 1979 and June 1984 18 adult patients with small noncleaved cell lymphoma (SNCL) (diffuse undifferentiated lymphoma, Burkitt's and non-Burkitt's types of the Rappaport classification) were treated with high-dose cyclophosphamide, doxorubicin, vincristine, prednisone, midcycle high-dose methotrexate, and intrathecal methotrexate. Early in the course of treatment, hyperfractionated radiotherapy (125 cGy, every two days, for 1,500 to 2,250 centigray [cGy]) was administered to unresected masses greater than 10 cm in their greatest dimension. Chemotherapy was administered every 21 days for six to ten cycles. Treatment was generally well tolerated; however, one patient died of probable tumor lysis syndrome. With a median follow-up of 1.2 years, actuarial survival was 66.8% and relapse-free survival (RFS) was 71.3% for the entire group. All treatment failures and deaths occurred in patients with stage D disease. RFS projected at 2 years was 100% for stages A and AR and 60.6% for stage B, C, and D (P = .13 Gehan). Two-year RFS for patients with stage A, AR, B, or C disease was 100 v 41% for those with stage D disease. Patients with adverse prognostic features (n = 7)--unresected bulk measuring greater than 10 cm, pretreatment serum lactate dehydrogenase (LDH) 500 IU/L (normal, 200) or involvement of CNS or bone marrow--had a projected RFS of 28.6% compared with 100% for those patients without these features (P = .002 Gehan). Too few patients received induction radiotherapy to assert its role in therapy. By using aggressive multiagent therapy, cure can be expected in a high percentage of adults with SNCL. In the subset with adverse prognostic features, more effective therapy is necessary.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0732-183X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
4
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
847-58
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:3711961-Abdominal Neoplasms,
pubmed-meshheading:3711961-Actuarial Analysis,
pubmed-meshheading:3711961-Adolescent,
pubmed-meshheading:3711961-Adult,
pubmed-meshheading:3711961-Aged,
pubmed-meshheading:3711961-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:3711961-Burkitt Lymphoma,
pubmed-meshheading:3711961-Combined Modality Therapy,
pubmed-meshheading:3711961-Cyclophosphamide,
pubmed-meshheading:3711961-Doxorubicin,
pubmed-meshheading:3711961-Female,
pubmed-meshheading:3711961-Humans,
pubmed-meshheading:3711961-Lymphoma,
pubmed-meshheading:3711961-Male,
pubmed-meshheading:3711961-Meningeal Neoplasms,
pubmed-meshheading:3711961-Methotrexate,
pubmed-meshheading:3711961-Middle Aged,
pubmed-meshheading:3711961-Neoplasm Staging,
pubmed-meshheading:3711961-Pelvic Neoplasms,
pubmed-meshheading:3711961-Prednisone,
pubmed-meshheading:3711961-Prognosis,
pubmed-meshheading:3711961-Vincristine
|
| pubmed:year |
1986
|
| pubmed:articleTitle |
Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types).
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|